Compression Devices and Bandaging Segment to Dominate MEA Lymphedema Treatment Market during 2021–2028

According to a new market research study on “MEA Lymphedema Treatment Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Condition Type, Treatment Type and End-User” is expected to reach US$ 237.30 million by 2028 from US$ 195.67 million in 2021. The market is estimated to grow at a CAGR of 2.8% from 2021 to 2028. The report provides trends prevailing in the MEA lymphedema treatment market along with the drivers and restraints pertaining to the market growth. Use of robotics for lymphedema treatment is the major factor driving the growth of the MEA lymphedema treatment market. However, issues associated with the lack of awareness and skilled professionals hinder the growth of MEA lymphedema treatment market.  

The MEA lymphedema treatment market is segmented into condition type, treatment type, end-user and country. Based on type, the MEA lymphedema treatment market is segmented into primary lymphedema and secondary lymphedema. The secondary lymphedema segment dominated the market in 2020 and primary lymphedema is expected to be the fastest growing during the forecast period. Based on treatment type, the MEA lymphedema treatment market is segmented into laser therapy, compression devices and bandaging, drug therapy, physiological procedures, debulking procedures, and others. The compression devices and bandaging segment dominated the market in 2020 and debulking procedures segment is expected to be the fastest growing during the forecast period. Further physiological procedures segment is bifurcated into lymphovenous anastomosis (LVA) and vascularised lymph node transfer (VLNT).Based on end-user, the MEA lymphedema treatment market is segmented into hospitals, clinics, clinical research organizations, and others. The hospitals segment dominated the market in 2020 and clinics is expected to be the fastest growing during the forecast period. Based on country, MEA lymphedema treatment market is classified into Saudi Arabia, South Africa, UAE, and Rest of MEA.

The coronavirus has shown substantial effects in the Middle East and Africa. Several growing COVID-19 cases have been reported, such as Iran (3,979,727), South Africa (2,236,805), Israel (882,798), UAE (685,462), and Saudi Arabia (528,952) on 4 August 2021. During the COVID-19 pandemic mass drug administration interventions neglected tropical diseases, including lymphatic filariasis have been halted. In view of current pandemic situation WHO issued the recommendation on 1st April 2020 t put all the community surveys, active cases finding activities and mass treatment campaigns on hold.

3M Company, BSN medical GmbH, Huntleigh Healthcare Limited, Lohmann & Rauscher GmbH & Co. KG, Mego Afek ltd, Sigvaris Group, and Smith & Nephew are among the leading companies in the MEA lymphedema treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Mego Afek ltd. has announced preliminary data for Lympha Press PCD-51 to be used in chronic venous stasis ulcers.

MEA Lymphedema Treatment Market, By Country, 2020 and 2028 (%)

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com